Angiotensin Converting Enzyme Inhibitors in Treatment of Covid 19
NCT ID: NCT04345406
Last Updated: 2020-04-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE3
60 participants
INTERVENTIONAL
2020-04-15
2029-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Coronavirus (COVID-19) ACEi/ARB Investigation
NCT04330300
Sacubitril/Valsartan Versus Valsartan in Heart Failure
NCT05881720
A Dose Finding Study Of PF-00489791 In Patients With Mild To Moderate High Blood Pressure
NCT00422461
A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting Conditions
NCT06273254
Efficacy and Safety of Azilsartan in Participants With Mild to Moderate Uncomplicated Essential Hypertension
NCT01289132
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ACEIs
ACEIs with conventional treatment for COVID19
ACEIs
Captopril or enalapril
Conventional treatment
alexoquine
Conventional treatment of COVID19
Conventional treatment of COVID19
Conventional treatment
alexoquine
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ACEIs
Captopril or enalapril
Conventional treatment
alexoquine
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tanta University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sherief Abd-Elsalam
assistant professor of tropical medicine and infectious diseases
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sherief Abd-Elsalam, ass. prof.
Role: PRINCIPAL_INVESTIGATOR
Tanta University Faculty of medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tanta University
Tanta, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ACEIS COVID 19
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.